Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134038 | 1.00 | HCAR2 (0.67) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL5128311 | 0.98 | HCAR2 (0.64) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL2268149 | 0.84 | HCAR2 (0.48) | HCAR2ATMCYP2C9CYP2C19HTT | |
| SCHEMBL3102318 | 0.80 | HCAR2 (0.69) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL185789 | 0.80 | HCAR2 (1.00) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL28807541 | 0.80 | HCAR2 (1.00) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL29586507 | 0.80 | HCAR2 (1.00) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL9507781 | 0.78 | HCAR2 (0.96) | HCAR2ATMSMYD3CYP2C9CYP2C19 | |
| SCHEMBL832732 | 0.78 | HCAR2 (0.67) | HCAR2ATMSMYD3HTTRAB9A | |
| Methyl Alcohol SCHEMBL28625386 | 0.78 | HCAR2 (0.96) | HCAR2ATMSMYD3CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358487-B | Lappaconitine derivative, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-08-25 | — | — | CN | claimed |
| WO-2022099937-A1 | LAPPACONITINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院新疆理化技术研究所 | 2022-05-19 | — | — | WO | claimed |
| CN-112358487-A | Lappaconitine derivative and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2021-02-12 | — | — | CN | claimed |
| CN-101531654-B | Preparation method for Rupatadine | ZHEJIANG CIFU PHARMACEUTICAL CO LTD | 2013-07-17 | — | — | CN | claimed |
| CN-101531654-A | Preparation method for Rupatadine | ZHEJIANG CIFU PHARMACEUTICAL C | 2009-09-16 | — | — | CN | claimed |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-12 | — | — | US | disclosed |
| CN-119462646-A | Substituted tetrahydro-beta-carboline derivative, synthesis method and application thereof | 江苏科技大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-113646307-B | Pyrido [3,4-d ] pyrimidin-8-one derivatives having protein kinase inhibitory activity and pharmaceutical compositions thereof | 韩国科学技术研究院 | 2024-07-30 | — | — | CN | disclosed |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2023-10-26 | — | — | US | disclosed |
| CN-112358487-B | Lappaconitine derivative, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-08-25 | — | — | CN | disclosed |
| CN-116496254-A | Preparation method of rupatadine fumarate | 南京海鲸药业股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-4405628-A | 4-Pyridylimidazolones and method of use | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-20 | — | — | US | disclosed |
| EP-0059948-A1 | Novel aroylimidazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | HCAR2 62/4885ATM 4154/4885SMYD3 4533/4885 |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | MCL1, CD47, BMI1 | HCAR2 1717/4885ATM 3080/4885SMYD3 981/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | HCAR2 62/4885ATM 4154/4885SMYD3 4533/4885 |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | HCAR2 493/4885ATM 1944/4885SMYD3 4816/4885 |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CCNC, CKS1B, CKS2 | HCAR2 2662/4885ATM 1895/4885SMYD3 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.